Anti-BCMAxCD3 Bispecific Antibody
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Anti-BCMAxCD3 Bispecific Antibody, covering 2026-04-13 to 2026-04-13. Get the full timeline:
Most recent: Clinical Trial Update: A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma [Phase 3]